Add BrightSurf on Google Email

Texas Tech University Health Sciences Center


TTUHSC researchers find blood-brain barrier remains resilient in Alzheimer’s disease model

A study published by TTUHSC researchers found that the blood-brain barrier remains intact in a commonly used mouse model of Alzheimer's disease, suggesting that drug delivery strategies may need to be redesigned. The discovery challenges long-standing assumptions about the impact of Alzheimer's on the brain's protective shield.

SourceTexas Tech University Health Sciences Center·JournalFluids and Barriers of the CNS·TypeObservational study·DateSep 29, 2025

TTUHSC conducting study to help patients that experience traumatic blood loss

The Texas Tech University Health Sciences Center is conducting a randomized controlled trial to investigate the effectiveness of calcium and vasopressin in treating severely injured patients who experience significant blood loss. The study, known as CAVALIER, will enroll approximately 1,050 participants aged 18-90.

SourceTexas Tech University Health Sciences Center·TypeRandomized controlled/clinical trial·DateFeb 28, 2025

TTUHSC researcher studies the ability of brine shrimp to thrive in high salinity

A research team at Texas Tech University Health Sciences Center discovered a unique sodium pump variant in brine shrimp that enables them to thrive in high-salinity environments. This NKA variant uses more energy than common variants, allowing the animal to maintain steeper Na+ gradients.

SourceTexas Tech University Health Sciences Center·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateDec 20, 2023

New specimen collection system enhances assisted reproductive technologies

A new specimen collection system has been developed to enhance assisted reproductive technologies by providing a simple one-step method for selecting high-quality sperm for ICSI. The system, known as NovaSort, uses a barrier mesh to isolate mobile sperm without damaging their DNA.

SourceTexas Tech University Health Sciences Center·JournalOpen Journal of Obstetrics and Gynecology·TypeExperimental study·DateOct 17, 2023

Stalking a silent killer

Researchers aim to treat pancreatic ductal adenocarcinoma by targeting amino acid transporter SLC6A14 and compensatory nutrient scavenging mechanisms autophagy and macropinocytosis. Using alpha-methyl-L-tryptophan and hydroxychlorquine, the study seeks to improve therapeutic outcomes in patients with pancreatic cancer.

TTUHSC-TTU research collaboration leads to possible drug targets for Leishmaniasis

The study found that drug-resistant Leishmania parasites have distinct protein production profiles compared to sensitive parasites, suggesting a global reprogramming of protein synthesis. This pre-emptive adaptation enables the parasite to quickly respond to the presence of the drug and survive when it is absent.

SourceTexas Tech University Health Sciences Center·JournalNature Communications·TypeExperimental study·DateJun 22, 2023

Researchers study the impact of cancer on Hispanic patients and their caregivers

A recent review article highlights the significant impact of cancer on Hispanic patients and their caregivers, citing communication barriers, financial difficulties, and sociocultural issues. The study estimates 126,000 new cancer cases diagnosed yearly in Hispanics, placing a substantial burden on family members and friends.

SourceTexas Tech University Health Sciences Center·JournalCancers·TypeData/statistical analysis·DateMar 20, 2023

Meta-analysis shows association between autism in children and cardiometabolic diseases

A meta-analysis of 34 studies found a significant association between autism spectrum disorder (ASD) and increased risks of developing diabetes, dyslipidemia, and heart disease. Children with ASD were more likely to develop these metabolic complications, prompting clinicians to monitor them closely.

SourceTexas Tech University Health Sciences Center·JournalJAMA Pediatrics·TypeMeta-analysis·DateMar 10, 2023

Study shows shaker channel mutation differs structurally from human potassium channels

A recent study led by Dr. Luis Cuello and Alain J. Labro found that a known Shaker channel mutation differs structurally from its human counterparts, with implications for drug development and ion transport mechanisms. The research reveals a unique conformation of the W434F mutant that is distinct from wild-type channels.

SourceTexas Tech University Health Sciences Center·JournalScience Advances·TypeObservational study·DateOct 11, 2022

New study explains mechanisms of salt transport and could help treat cystic fibrosis

A recent study by Texas Tech University Health Sciences Center researchers has shed light on the mechanisms of salt transport across membrane barriers. The findings have significant implications for treating cystic fibrosis, a disease caused by mutations in three types of sodium-potassium pumps.

SourceTexas Tech University Health Sciences Center·JournalNature Communications·TypeObservational study·DateSep 21, 2022

Research identifies, exploits vulnerability in certain high-risk cancers

A recent study published in Cancer Research identified a unique vulnerability in certain high-risk cancers that can be exploited for targeted therapy. Researchers found that cancer cells with alternative lengthening of telomeres (ALT) have a common weakness, leading to resistance to DNA-damaging agents and chemotherapy.

SourceTexas Tech University Health Sciences Center·JournalCancer Research·TypeExperimental study·DateAug 10, 2022

TTUHSC technology leads successful clinical trial to treat dry eye disease

A clinical trial conducted by TTUHSC researchers found that corneal epithelial stem cell-derived eye drops significantly improved symptoms of severe dry eye disease, with patients experiencing a 23% improvement in SPEED questionnaire scores and a 17.1% improvement in OSDI scores. No adverse reactions were reported during the 12-week tr...

SourceTexas Tech University Health Sciences Center·JournalJournal of Clinical Ophthalmology·TypeRandomized controlled/clinical trial·DateSep 28, 2021